Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	41509
Country	Japan

Received	2018-08-27 01:02
Peer-Review Started	2018-08-27 07:07
To Make the First Decision	2018-09-03 02:05
Return for Revision	2018-09-11 00:31
Revised	2018-09-17 10:52
Second Decision	2018-11-01 03:04
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-11-02 22:09
Articles in Press	2018-11-02 22:09
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-12-05 08:27
Publish the Manuscript Online	2018-12-14 10:51

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Letter to the Editor
Article Title	Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
Manuscript Source	Unsolicited Manuscript
All Author List	Yu Sunakawa, Hironaga Satake and Wataru Ichikawa
ORCID	Author(s) ORCID Number Yu Sunakawa http://orcid.org/0000-0002-0163-7543 Hironaga Satake http://orcid.org/0000-0001-7629-6803 Wataru Ichikawa http://orcid.org/0000-0001-5543-4488
Funding Agency and Grant Number
Corresponding Author	Yu Sunakawa, MD, PhD, Associate Professor, Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki 216-8511, Kanagawa, Japan. y.suna0825@gmail.com
Key Words	Tumor sidedness; FOLFOXIRI; Bevacizumab; Colorectal cancer; RAS mutation
Core Tip	FOLFOXIRI plus bevacizumab regimen might be a preferred option for the first-line treatment of only right-sided metastatic colorectal cancer (mCRC) regardless of RAS or BRAF status. However, subanalysis of a phase Ⅱ trial of the triplet plus bevacizumab in patients with RAS mutant mCRC demonstrated that more patients with left-sided tumors achieved good tumor shrinkage and long duration of treatment than did patients with right-sided tumors, leading to higher rate of conversion to surgery in mCRC patients with left-sided tumors. Our data suggest that FOLFOXIRI plus bevacizumab may be a promising treatment for left-sided mCRC associated with RAS mutant tumors.
Publish Date	2018-12-14 10:51
Citation	Sunakawa Y, Satake H, Ichikawa W. Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors. World J Gastrointest Oncol 2018; 10(12): 528-531
URL	https://www.wjgnet.com/1948-5204/full/v10/i12/528.htm
DOI	https://dx.doi.org/10.4251/wjgo.v10.i12.528

Full Article (PDF)	WJGO-10-528.pdf
Full Article (Word)	WJGO-10-528.docx
Manuscript File	41509-Review.docx
Answering Reviewers	41509-Answering reviewers.pdf
Audio Core Tip	41509-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	41509-Conflict-of-interest statement.pdf
Copyright License Agreement	41509-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	41509-Language certificate.pdf
Peer-review Report	41509-Peer-review(s).pdf
Scientific Misconduct Check	41509-Scientific misconduct check.pdf
Scientific Editor Work List	41509-Scientific editor work list.pdf